Atezolizumab with nab-paclitaxel for untreated PD-L1-positive, locally advanced or metastatic, triple-negative breast cancer
Technology appraisal guidance
Reference number: TA639
Published:
The committee meeting scheduled for 12 November 2019 has been postponed while commercial discussions are ongoing. An update will be provided once we confirm the next steps.